Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Filament Health Corp N.FH

Alternate Symbol(s):  FLHLF

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of psilocybe cubensis fruiting bodies include: PEX010 Psilocybin ... see more

Recent & Breaking News (NEO:FH)

Filament Health Announces Annual General Meeting Voting Results

Newsfile November 8, 2023

Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications

Accesswire October 23, 2023

FILAMENT HEALTH ANNOUNCES HEALTH CANADA AUTHORIZATION FOR PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR OPIOID USE DISORDER

Canada NewsWire October 10, 2023

FILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING LED BY NEGEV CAPITAL

Canada NewsWire September 29, 2023

FILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA BIOSCIENCES COMPLETES IMPORT OF COCA LEAF FROM PERU

Canada NewsWire September 21, 2023

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD

Accesswire September 21, 2023

FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA

Canada NewsWire August 31, 2023

FILAMENT HEALTH AND NASDAQ-LISTED SPAC JUPITER ACQUISITION CORP. ANNOUNCE FILING OF SEC REGISTRATION STATEMENT

Canada NewsWire August 15, 2023

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND REFILES Q1 2023 INTERIM FINANCIAL STATEMENTS AND MD&A

Canada NewsWire August 15, 2023

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS BOTANICAL PSILOCYBIN DRUG CANDIDATE PEX010

Canada NewsWire August 8, 2023

FILAMENT HEALTH ANNOUNCES UPSIZING AND CLOSING OF $2,500,000 NON-BROKERED PRIVATE PLACEMENT FINANCING

Canada NewsWire July 24, 2023

FILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING OF UP TO C$2,000,000

Canada NewsWire July 19, 2023

FILAMENT HEALTH CORP. TO LIST ON NASDAQ THROUGH BUSINESS COMBINATION WITH JUPITER ACQUISITION CORPORATION

Canada NewsWire July 19, 2023

FILAMENT HEALTH ANNOUNCES CHANGE OF AUDITOR

Canada NewsWire July 14, 2023

FILAMENT HEALTH TO SUPPLY PSILOCYBIN FOR RECIPIENTS OF THE CANADIAN INSTITUTES OF HEALTH RESEARCH PSILOCYBIN OPERATING GRANTS

Canada NewsWire July 6, 2023

Filament Health enters exclusive licensing deal with NeoLumina

Brieanna McCutcheon  June 30, 2023

FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT WITH NEOLUMINA BIOSCIENCE INC.

Canada NewsWire June 30, 2023

FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO

Canada NewsWire May 30, 2023

FILAMENT HEALTH ANNOUNCES FIRST EVER NAGOYA PROTOCOL-COMPLIANT SHIPMENT OF IBOGA FROM GABON

Canada NewsWire May 17, 2023

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire May 12, 2023